Table 2.
Overview of genes for the analysis of interactions between the effect of the radiation dose and the donor group
| Gene | Genename | N2+ /N1 vs. N0 | N1 vs. N0 | N2+ vs. N0 | N2+ vs. N1 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| FDR | LFC | FDR | LFC | FDR | LFC | FDR | LFC | |||
| 0.05 Gray | RAB41 | RAB41, member RAS oncogene family | 0.404 | − 0.567 | 0.166 | − 0.757 | – | – | – | – |
| CAMTA2 | Calmodulin binding transcription activator 2 | 0.404 | 0.074 | – | – | 0.056 | 0.101 | - | - | |
| PATZ1 | POZ/BTB and AT hook containing zinc finger 1 | 0.404 | − 0.077 | – | – | – | – | – | – | |
| RIPK1 | Receptor interacting serine/threonine kinase 1 | 0.404 | − 0.060 | – | – | – | – | – | – | |
| SPDYE3 | Speedy/RINGO cell cycle regulator family member E3 | 0.404 | − 0.202 | – | – | – | – | – | – | |
| ZNF226 | Zinc finger protein 226 | 0.404 | − 0.097 | – | – | – | – | – | – | |
| AGAP9 | ArfGAP with GTPase domain, ankyrin repeat and PH domain 9 | – | – | 0.359 | 0.826 | – | – | – | – | |
| PDZD2 | PDZ domain containing 2 | – | – | 0.727 | 0.758 | – | – | – | – | |
| COL23A1 | Collagen type XXIII alpha 1 chain | – | – | - | – | 0.536 | 0.840 | – | – | |
| ADNP-AS1 | ADNP antisense RNA 1 | – | – | – | – | – | – | 0.457 | 0.533 | |
| ALG9 | ALG9 alpha-1,2-mannosyltransferase | – | – | – | – | – | – | 0.457 | -0.171 | |
| CLUHP3 | Clustered mitochondria homolog pseudogene 3 | – | – | – | – | – | – | 0.457 | 0.553 | |
| DLEU2 | Deleted in lymphocytic leukemia 2 | – | – | – | – | – | – | 0.457 | -0.378 | |
| LOC101927630 | Uncharacterized LOC101927630 | – | – | – | – | – | – | 0.457 | -0.824 | |
| MYO7B | Myosin VIIB | – | – | – | – | – | – | 0.457 | 0.877 | |
| TFCP2 | Transcription factor CP2 | – | – | – | – | – | – | 0.457 | -0.071 | |
| TIAF1 | TGFB1-induced anti-apoptotic factor 1 | – | – | – | – | – | – | 0.457 | 0.342 | |
| LINC02257 | Long intergenic non-protein coding RNA 2257 | – | – | – | – | – | – | 0.624 | 0.777 | |
| 2 Gray | LINC00601 | Long intergenic non-protein coding RNA 601 | 0.003 | 0.552 | 0.001 | 0.692 | – | – | – | – |
| COBLL1 | Cordon-bleu WH2 repeat protein like 1 | 0.003 | 0.258 | 0.005 | 0.282 | – | – | – | – | |
| SESN2 | Sestrin 2 | 0.003 | 0.218 | 0.015 | 0.229 | 0.193 | 0.208 | – | – | |
| BIN3 | Bridging integrator 3 | 0.003 | −0.130 | 0.024 | − 0.131 | 0.193 | -0.128 | – | – | |
| TNFRSF10A | TNF receptor superfamily member 10a | 0.003 | 0.317 | 0.001 | 0.409 | – | – | – | – | |
| EEF1AKNMT | eEF1A lysine and N-terminal methyltransferase | 0.013 | 0.101 | 0.013 | 0.118 | – | – | – | – | |
| MGAT4A | alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A | 0.093 | 0.805 | 0.427 | 0.760 | 0.324 | 0.851 | – | – | |
| CTPS2 | CTP synthase 2 | 0.130 | − 0.113 | – | – | – | – | – | – | |
| BTG2 | BTG anti-proliferation factor 2 | 0.157 | 0.173 | 0.004 | 0.256 | – | – | – | – | |
| ZNF598 | Zinc finger protein 598 | 0.157 | − 0.105 | – | – | – | – | – | – | |
| IP6K3 | Inositol hexakisphosphate kinase 3 | – | – | 0.339 | − 0.787 | – | – | – | – | |
| PDZD2 | PDZ domain containing 2 | – | – | 0.434 | 0.755 | – | – | – | – | |
| ADAMTS17 | ADAM metallopeptidase with thrombospondin type 1 motif 17 | – | – | – | – | – | – | 0.469 | − 0.833 | |
| DUOXA1 | Dual oxidase maturation factor 1 | – | – | – | – | 0.324 | 0.750 | 0.472 | 0.828 | |
| EDARADD | EDAR associated death domain | – | – | – | – | 0.324 | 0.769 | – | – | |
| HAS3 | Hyaluronan synthase 3 | – | – | – | – | – | – | 0.469 | 0.711 | |
| LOC100505622 | Uncharacterized LOC100505622 | – | – | – | – | – | – | 0.469 | − 0.737 | |
| TSEN54 | tRNA splicing endonuclease subunit 54 | – | – | – | – | 0.193 | − 0.175 | – | – | |
| ZNF2 | Zinc finger protein 2 | – | – | – | – | – | – | 0.469 | − 0.140 | |
Genes were selected if their p-value was among the top 0.01% of that data set, p-value < 0.15, or log2 fold-change >|0.75|
Data adjusted for age at sampling and sex (model 1) are shown. Genes with p-value < 0.05 adjusted for false discovery rate (FDR) are presented in bold text
N2+ = fibroblasts of donors with a first primary neoplasm in childhood and at least one second primary neoplasm, N1 = fibroblasts of donors with a first primary neoplasm in childhood, N0 = fibroblasts of cancer-free controls; LFC = log2 fold-change